Ohio State Navbar

Richard M. Goldberg, MD, Awarded Society for Translational Oncology (STO)'s Pinedo Prize



4/10/2015 11:20:32 AM

DURHAM, N.C., April 10, 2015 /PRNewswire-iReach/ -- The Society for Translational Oncology (STO) is pleased to announce that Richard M. Goldberg, MD, internationally renowned gastrointestinal oncologist and physician-in-chief at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James), has been named recipient of the 2015 Bob Pinedo Cancer Care Prize. The award recognizes Dr. Goldberg's clinical and research leadership in the areas of gastrointestinal cancers, coupled with his compassionate care of cancer patients.

This year's Pinedo Prize of $50,000 will be presented at the STO Fifth Annual meeting, to be hosted by OSUCCC James at the Biomedical Research Tower (BRT) in Columbus, Ohio on April 10-11, 2015. Dr. Goldberg will deliver the keynote lecture at the meeting which will be published by The Oncologist, STO's official journal.

A respected expert in colorectal cancer, Dr. Goldberg has led a national intergroup study N9741 as part of an international phase III study of oxaliplatin, irinotecan and 5-fluorouracil in combinations for first-line treatment of advanced colorectal cancer. This study, which resulted in approval of oxaliplatin for clinical use, was conducted in centers across the United States and Canada. It helped change the standard of care for patients with advanced colorectal cancer.

"I'm proud and humbled to be honored with this award," commented Dr. Goldberg, "This is particularly meaningful to me since the STO meeting will be held in Columbus this year. Honoring Prof. Pinedo's name as a recipient of this award in many ways provides a fitting symmetry, highlighting the ways that our paths have intersected over almost four decades, and bracketing his career and mine."

Dr. Goldberg's clinical interests include colorectal and other gastrointestinal (GI) cancers, carcinoid and GI tract neuroendocrine tumors, new drug development and inherited predisposition to GI cancers. His research focuses on clinical studies in patients with GI cancers (principally colorectal), translational studies with laboratory collaborators on biologic specimens from patients with cancer, development of new cancer drugs and drug combinations, and clinical trials methodology.

"I am delighted that Dr. Richard Goldberg is this year's Pinedo Prize recipient.  He is an outstanding clinician and cancer researcher whose work, particularly in gastrointestinal cancers, has benefitted patients across the world," commented Prof. Patrick G. Johnston, co-chair of STO and gastrointestinal section editor of The Oncologist.   

The Pinedo Cancer Care Prize honors Professor H.M. (Bob) Pinedo, founder of the VU University Medical Center (VUmc) Cancer Center Amsterdam (CCA), who weds world-class cancer research with a devotion to his patients and their families. In the past eight years, the Bob Pinedo Cancer Care Prize has been awarded to:

Bruce A. Chabner, MD Massachusetts General Hospital Cancer Center

Joseph R. Bertino, MD The Cancer Institute of New Jersey

Bob Löwenberg, MD Erasmus University Medical Centre

Richard J. O'Reilly, MD Memorial Sloan Kettering Cancer Center

José Baselga, MD, PhD Memorial Sloan Kettering Cancer Center

Gabriel N. Hortobágyi, MD The University of Texas MD Anderson Cancer Center

Richard L. Schilsky, MD  University of Chicago

Patrick G. Johnston, MD Queen's University Belfast

About the Society for Translational Oncology

STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist. For more information, visit: www.sto-online.org.

About The Oncologist

Recognized as a premier peer-reviewed cancer medicine journal, The Oncologist, now in its twentieth year, is devoted to physicians entrusted with the care of cancer patients. The Oncologist is the official journal of the Society for Translational Oncology. For more information, visit: www.theoncologist.com.

About The OSUCCC James

The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs. As the cancer program's 306-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. At 21 floors with more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. For more information, visit cancer.osu.edu.

For more information, contact:

Gabby Cruze, Executive Director, STO
Tel: (919) 433-0489

Amanda Harper, OSUCCC James
Tel: (614) 685-5420

Media Contact: Gabby Cruze, Society for Translational Oncology, (919) 433-0489, gabby.cruze@sto-online.org

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


SOURCE Society for Translational Oncology